January 17, 2021
Business News

KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies

CAMBRIDGE, Mass.–()–KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced that it has entered into a broad strategic collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) to research, develop and commercialize novel immune-based therapies for cancer. Under the agreement, KSQ has granted Takeda an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize cell and non-cell therapy products that modulate targets identified using KSQ’s CRISPRomics technology. The deal includes two T-cell targets…

Click here to view the original article.

Related Posts

You might also like ...

post featured image
One measure of unemployment suggests Biden’s $1.9 trillion stimulus plan could do more harm than good, sa.. – Business Insider
post featured image
France pushes suspension of EU-US trade dispute – POLITICO.eu
post featured image
Your next stimulus check — for $1,400 — will move closer this week